Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline

Taccone, FS; Rodríguez-Villalobos, Hector; Backer, Daniel De; Moor, Véronique De; Devière, Jacques; Vincent, Jean‐Louis; Jacobs, Frédérique

doi:10.1007/s10096-006-0123-1

Cited by 85 publications

(50 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the effect of TGC combination therapy for bacteremia or bloodstream infection caused by MDR A. baumannii has been reported in previous studies (5,15) and case reports of septic shock patients complicated with trauma and acute pancreatitis (21,22). The addition of TGC to conventional therapy in patients with XDR A. baumannii-associated VAP decreased the incidence of septic shock, as first reported in the current study.…”

Section: Discussionsupporting

confidence: 83%

Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii

He¹,

Zheng²,

Sun³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Extensive drug-resistant Acinetobacter baumannii (XDR A. baumannii) has emerged as an important pathogen in patients with ventilator-associated pneumonia (VAP) worldwide. This study determined whether or not combination tigecycline (TGC) treatment improved the short-term outcome of patients with XDR A. baumannii-induced VAP. Methods: Fifty-eight patients admitted to our intensive care unit (ICU) with confirmed XDR A. baumannii VAP between January 2011 and June 2013 were retrospectively studied. Fourteen patients were excluded. The included subjects were classified into two groups depending on treatment regimens with or without TGC (TGC group, n=20; non-TGC group, n=24). Thirty-day mortality rates, and clinical and microbiologic responses were reviewed and compared in detail.

show abstract

Section: Discussionsupporting

confidence: 83%

Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii

He¹,

Zheng²,

Sun³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Inducing rapid protective im- (33,34). One approach that is being developed for the treatment of other highly resistant bacteria, such as S. aureus and P. aeruginosa, is the use of antibody-based therapies (3,8).…”

Section: Discussionmentioning

confidence: 99%

“…However, the emergence of strains resistant to colistin has now been reported (1,5). Of particular concern are recent reports describing outbreaks of panresistant strains, which are resistant to all standard antimicrobials (33,34). Given these trends, the development of new strategies for preventing and treating infections caused by this pathogen is necessary.…”

mentioning

confidence: 99%

Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii

et al. 2011

View full text Add to dashboard Cite

Acinetobacter baumannii causes pneumonias, bacteremias, and skin and soft tissue infections, primarily in the hospitalized setting. The incidence of infections caused by A. baumannii has increased dramatically over the last 30 years, while at the same time the treatment of these infections has been complicated by the emergence of antibiotic-resistant strains. Despite these trends, no vaccines or antibody-based therapies have been developed for the prevention of A. baumannii infection. In this study, an outer membrane complex vaccine consisting of multiple surface antigens from the bacterial membrane of A. baumannii was developed and tested in a murine sepsis model. Immunization elicited humoral and cellular responses that were able to reduce postinfection bacterial loads, reduce postinfection proinflammatory cytokine levels in serum, and protect mice from infection with human clinical isolates of A. baumannii. A single administration of the vaccine was able to elicit protective immunity in as few as 6 days postimmunization. In addition, vaccine antiserum was used successfully to therapeutically rescue naïve mice with established infection. These results indicate that prophylactic vaccination and antibody-based therapies based on an outer membrane complex vaccine may be viable approaches to preventing the morbidity and mortality caused by this pathogen.

show abstract

“…Unfortunately, colistinresistant clinical isolates of A. baumannii have been reported (1)(2)(3). Two mechanisms for acquiring colistin resistance have been described in A. baumannii: ethanolamine addition to the lipid A moiety of lipopolysaccharide (LPS) resulting from mutations in the PmrAB two-component system (4,5) and complete loss of LPS expression due to mutation in the lpxA, lpxC, and lpxD genes, which encode the enzymes that catalyze the first steps in LPS biosynthesis (6,7).…”

mentioning

confidence: 99%

Activity of Host Antimicrobials against Multidrug-Resistant Acinetobacter baumannii Acquiring Colistin Resistance through Loss of Lipopolysaccharide

García-Quintanilla

Pulido

Moreno-Martínez

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Acinetobacter baumannii can acquire resistance to the cationic peptide antibiotic colistin through complete loss of lipopolysaccharide (LPS) expression. The activities of the host cationic antimicrobials LL-37 and human lysozyme against multidrug-resistant clinical isolates of A. baumannii that acquired colistin resistance through lipopolysaccharide loss were characterized. We demonstrate that LL-37 has activity against strains lacking lipopolysaccharide that is similar to that of their colistin-sensitive parent strains, whereas human lysozyme has increased activity against colistin-resistant strains lacking LPS.

show abstract

Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline

Cited by 85 publications

References 11 publications

Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii

Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii

Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii

Activity of Host Antimicrobials against Multidrug-Resistant Acinetobacter baumannii Acquiring Colistin Resistance through Loss of Lipopolysaccharide

Contact Info

Product

Resources

About